Oric Capital Surpluse vs Total Stockholder Equity Analysis

ORIC Stock

USD 9.41 0.22 2.28%

Oric Pharmaceuticals financial indicator trend analysis is much more than just breaking down Oric Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oric Pharmaceuticals is a good investment. Please check the relationship between Oric Pharmaceuticals Capital Surpluse and its Total Stockholder Equity accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.

Capital Surpluse vs Total Stockholder Equity

Capital Surpluse vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oric Pharmaceuticals Capital Surpluse account and Total Stockholder Equity. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Oric Pharmaceuticals' Capital Surpluse and Total Stockholder Equity is 0.94. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Oric Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Oric Pharmaceuticals' Capital Surpluse and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Oric Pharmaceuticals are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Capital Surpluse i.e., Oric Pharmaceuticals' Capital Surpluse and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.94

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Capital Surpluse

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most indicators from Oric Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oric Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.The current year's Enterprise Value is expected to grow to about 577.8 M, whereas Selling General Administrative is forecasted to decline to about 17.5 M.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	86.8M	110.8M	142.9M	74.4M
Cost Of Revenue	966K	1.0M	1.2M	1.0M

Total Operating Expenses Cost Of Revenue

Oric Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Capital Surpluse	Net Invested Capital
Total Assets		0.81	0.88	0.97	-0.96	0.97	0.28	0.95	-0.59	-0.8	0.51	0.63	0.71	0.69	0.83	0.99	0.57	-0.09	0.92	0.83	0.17	0.99	0.92	0.01	0.97	0.99
Other Current Liab	0.81		0.91	0.77	-0.86	0.85	0.39	0.86	-0.29	-0.99	0.46	0.39	0.57	0.6	0.75	0.81	0.8	-0.09	0.82	0.98	0.19	0.81	0.9	0.34	0.84	0.82
Total Current Liabilities	0.88	0.91		0.85	-0.88	0.86	0.47	0.93	-0.36	-0.93	0.57	0.41	0.69	0.7	0.84	0.86	0.87	-0.09	0.92	0.93	0.2	0.87	0.99	0.43	0.95	0.87
Total Stockholder Equity	0.97	0.77	0.85		-0.91	0.95	0.26	0.89	-0.57	-0.75	0.54	0.61	0.68	0.66	0.69	0.97	0.57	-0.31	0.88	0.79	-0.07	0.97	0.89	0.02	0.94	0.97
Other Liab	-0.96	-0.86	-0.88	-0.91		-0.91	-0.31	-0.96	0.55	0.85	-0.36	-0.61	-0.69	-0.67	-0.84	-0.96	-0.56	0.01	-0.87	-0.88	-0.25	-0.96	-0.92	0.01	-0.92	-0.98
Net Tangible Assets	0.97	0.85	0.86	0.95	-0.91		0.3	0.87	-0.49	-0.84	0.61	0.55	0.69	0.66	0.8	0.96	0.58	-0.14	0.9	0.85	0.12	0.96	0.9	0.1	0.95	0.94
Property Plant And Equipment Net	0.28	0.39	0.47	0.26	-0.31	0.3		0.26	0.26	-0.45	0.03	-0.2	0.43	-0.1	0.33	0.24	0.44	-0.06	0.26	0.43	0.08	0.24	0.45	0.37	0.37	0.27
Current Deferred Revenue	0.95	0.86	0.93	0.89	-0.96	0.87	0.26		-0.51	-0.85	0.39	0.55	0.61	0.69	0.86	0.95	0.68	0.01	0.89	0.86	0.28	0.95	0.95	0.12	0.93	0.95
Net Debt	-0.59	-0.29	-0.36	-0.57	0.55	-0.49	0.26	-0.51		0.23	-0.47	-0.99	-0.65	-0.7	-0.44	-0.55	-0.09	-0.02	-0.65	-0.36	-0.12	-0.54	-0.33	0.43	-0.45	-0.59
Retained Earnings	-0.8	-0.99	-0.93	-0.75	0.85	-0.84	-0.45	-0.85	0.23		-0.49	-0.32	-0.59	-0.62	-0.78	-0.79	-0.83	0.07	-0.83	-0.98	-0.22	-0.8	-0.93	-0.43	-0.86	-0.8
Accounts Payable	0.51	0.46	0.57	0.54	-0.36	0.61	0.03	0.39	-0.47	-0.49		0.49	0.66	0.75	0.46	0.46	0.58	-0.27	0.74	0.53	-0.1	0.46	0.5	0.45	0.61	0.44
Cash	0.63	0.39	0.41	0.61	-0.61	0.55	-0.2	0.55	-0.99	-0.32	0.49		0.7	0.72	0.48	0.59	0.14	0.01	0.69	0.45	0.13	0.59	0.39	-0.4	0.5	0.64
Non Current Assets Total	0.71	0.57	0.69	0.68	-0.69	0.69	0.43	0.61	-0.65	-0.59	0.66	0.7		0.76	0.69	0.63	0.46	-0.04	0.82	0.7	0.16	0.63	0.64	0.12	0.73	0.69
Non Currrent Assets Other	0.69	0.6	0.7	0.66	-0.67	0.66	-0.1	0.69	-0.7	-0.62	0.75	0.72	0.76		0.67	0.64	0.56	-0.04	0.83	0.71	0.16	0.64	0.65	0.24	0.72	0.67
Other Assets	0.83	0.75	0.84	0.69	-0.84	0.8	0.33	0.86	-0.44	-0.78	0.46	0.48	0.69	0.67		0.81	0.55	0.41	0.86	0.78	0.64	0.81	0.84	0.19	0.87	0.79
Cash And Short Term Investments	0.99	0.81	0.86	0.97	-0.96	0.96	0.24	0.95	-0.55	-0.79	0.46	0.59	0.63	0.64	0.81		0.55	-0.09	0.88	0.8	0.16	1.0	0.91	-0.02	0.95	0.99
Common Stock Shares Outstanding	0.57	0.8	0.87	0.57	-0.56	0.58	0.44	0.68	-0.09	-0.83	0.58	0.14	0.46	0.56	0.55	0.55		-0.26	0.72	0.81	-0.01	0.55	0.81	0.74	0.7	0.55
Non Current Liabilities Total	-0.09	-0.09	-0.09	-0.31	0.01	-0.14	-0.06	0.01	-0.02	0.07	-0.27	0.01	-0.04	-0.04	0.41	-0.09	-0.26		-0.05	-0.09	0.96	-0.09	-0.11	-0.17	-0.1	-0.14
Other Current Assets	0.92	0.82	0.92	0.88	-0.87	0.9	0.26	0.89	-0.65	-0.83	0.74	0.69	0.82	0.83	0.86	0.88	0.72	-0.05		0.87	0.22	0.89	0.89	0.22	0.94	0.89
Other Stockholder Equity	0.83	0.98	0.93	0.79	-0.88	0.85	0.43	0.86	-0.36	-0.98	0.53	0.45	0.7	0.71	0.78	0.8	0.81	-0.09	0.87		0.19	0.81	0.92	0.37	0.87	0.84
Total Liab	0.17	0.19	0.2	-0.07	-0.25	0.12	0.08	0.28	-0.12	-0.22	-0.1	0.13	0.16	0.16	0.64	0.16	-0.01	0.96	0.22	0.19		0.16	0.18	-0.04	0.17	0.12
Total Current Assets	0.99	0.81	0.87	0.97	-0.96	0.96	0.24	0.95	-0.54	-0.8	0.46	0.59	0.63	0.64	0.81	1.0	0.55	-0.09	0.89	0.81	0.16		0.92	-0.01	0.95	0.99
Common Stock	0.92	0.9	0.99	0.89	-0.92	0.9	0.45	0.95	-0.33	-0.93	0.5	0.39	0.64	0.65	0.84	0.91	0.81	-0.11	0.89	0.92	0.18	0.92		0.35	0.97	0.91
Property Plant Equipment	0.01	0.34	0.43	0.02	0.01	0.1	0.37	0.12	0.43	-0.43	0.45	-0.4	0.12	0.24	0.19	-0.02	0.74	-0.17	0.22	0.37	-0.04	-0.01	0.35		0.26	-0.03
Capital Surpluse	0.97	0.84	0.95	0.94	-0.92	0.95	0.37	0.93	-0.45	-0.86	0.61	0.5	0.73	0.72	0.87	0.95	0.7	-0.1	0.94	0.87	0.17	0.95	0.97	0.26		0.94
Net Invested Capital	0.99	0.82	0.87	0.97	-0.98	0.94	0.27	0.95	-0.59	-0.8	0.44	0.64	0.69	0.67	0.79	0.99	0.55	-0.14	0.89	0.84	0.12	0.99	0.91	-0.03	0.94

Click cells to compare fundamentals

Oric Pharmaceuticals Account Relationship Matchups

Oric Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	299.0M	298.6M	247.2M	252.0M	274.1M	212.0M
Other Current Liab	8.2M	11.3M	11.4M	16.8M	23.3M	24.5M
Total Current Liabilities	9.0M	15.2M	15.4M	20.5M	24.8M	13.1M
Total Stockholder Equity	289.8M	273.0M	222.4M	224.1M	243.1M	179.0M
Net Tangible Assets	(90.1M)	289.8M	273.0M	222.4M	255.7M	268.5M
Property Plant And Equipment Net	2.0M	2.4M	3.3M	12.0M	2.9M	4.2M
Net Debt	(78.4M)	(224.1M)	(64.2M)	(13.2M)	(56.2M)	(59.0M)
Retained Earnings	(166.4M)	(245.1M)	(334.2M)	(434.9M)	(562.8M)	(534.6M)
Accounts Payable	757K	1.9M	1.3M	944K	1.5M	1.1M
Cash	78.4M	226.0M	66.8M	23.4M	59.4M	84.1M
Non Current Assets Total	2.3M	58.1M	36.7M	39.4M	11.9M	21.9M
Non Currrent Assets Other	319K	12.3M	11.5M	552K	9.0M	5.0M
Other Assets	0.0	319K	521K	517K	594.6K	339.7K
Cash And Short Term Investments	293.6M	237.0M	206.3M	208.2M	256.0M	186.8M
Common Stock Shares Outstanding	21.9M	38.0M	39.7M	51.5M	69.7M	41.2M
Liabilities And Stockholders Equity	299.0M	298.6M	247.2M	252.0M	274.1M	212.0M
Non Current Liabilities Total	219K	10.5M	9.4M	7.5M	6.2M	5.9M
Other Current Assets	3.1M	7.1M	4.2M	4.4M	6.3M	3.8M
Other Stockholder Equity	157.2M	518.2M	557.9M	658.8M	805.5M	845.8M
Total Liab	9.2M	25.7M	24.8M	27.9M	31.0M	24.0M
Total Current Assets	296.7M	240.5M	210.5M	212.6M	262.3M	190.1M
Accumulated Other Comprehensive Income	(31K)	(103K)	(1.3M)	258K	379K	398.0K
Property Plant Equipment	2.2M	2.0M	2.4M	3.3M	3.7M	2.8M
Capital Surpluse	2.6M	456.2M	518.2M	557.9M	641.5M	338.0M
Net Invested Capital	289.8M	273.0M	222.4M	224.1M	243.1M	200.5M
Property Plant And Equipment Gross	2.0M	7.4M	9.0M	9.4M	10.4M	6.7M
Net Working Capital	287.7M	225.4M	195.1M	192.1M	237.4M	198.5M
Short Term Debt	546K	1.9M	2.7M	2.8M	3.2M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

UBER	Uber Technologies
APP	Applovin Corp
RYAAY	Ryanair Holdings PLC

When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:

How To Invest In Oric

Details

Is Oric Stock a good investment?

Details

What is Oric Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.

You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.88)

Return On Assets

(0.31)

Return On Equity

(0.48)

The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Oric Capital Surpluse vs Total Stockholder Equity Analysis

Capital Surpluse vs Total Stockholder Equity

Capital Surpluse vs Total Stockholder Equity Correlation Analysis

Correlation Coefficient

Capital Surpluse

Total Stockholder Equity

Oric Pharmaceuticals fundamental ratios Correlations

Oric Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oric Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Total Assets
Common Stock	+ 0.99	Total Current Liabilities
Net Invested Capital	+ 0.99	Cash And Short Term Investments

Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Other Current Liab
Other Stockholder Equity	- 0.98	Retained Earnings
Net Invested Capital	- 0.98	Other Liab
Total Current Assets	- 0.96	Other Liab
Cash And Short Term Investments	- 0.96	Other Liab